Merck & Co., Inc. Research and Development in Process
Merck & Co., Inc. (MRK) reported Research and Development in Process of $1.56 billion for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-05.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2021-11-05
- Merck & Co., Inc. research and development in process for the quarter ending 2021-09-30 was $0.00.
- Merck & Co., Inc. research and development in process for the quarter ending 2020-12-31 was $0.00, a 100.00% decline year-over-year.
- Merck & Co., Inc. research and development in process for the quarter ending 2020-09-30 was $0.00.
- Merck & Co., Inc. research and development in process for the quarter ending 2019-12-31 was $11.00M.
- Merck & Co., Inc. research and development in process for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- Merck & Co., Inc. research and development in process for fiscal 2019 was $993.00M.
- Merck & Co., Inc. research and development in process for fiscal 2018 was $0.00.
- Merck & Co., Inc. research and development in process for fiscal 2017 was $0.00.
| Period end | Research and Development in Process 3 month | Research and Development in Process 6 month | Research and Development in Process 9 month | Research and Development in Process 12 month |
|---|---|---|---|---|
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $1.56B 10-Q · filed 2021-11-05 | ||
| 2021-06-30 | $1.56B 10-Q · filed 2021-08-09 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $0.00 derived: sum of 2 quarters · filed 2021-11-05 | $0.00 10-K · filed 2021-02-25 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $0.00 10-Q · filed 2021-11-05 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-09 | |||
| 2019-12-31 | $11.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $993.00M 10-K · filed 2021-02-25 | ||
| 2019-09-30 | $982.00M 10-Q · filed 2020-11-05 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $0.00 10-K · filed 2021-02-25 | ||
| 2018-09-30 | $0.00 10-Q · filed 2019-11-05 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-02-26 | |||
| 2009-12-31 | $0.00 10-K · filed 2010-03-01 | |||
| 2008-12-31 | $0.00 10-K · filed 2010-03-01 | |||
| 2007-12-31 | $325.10M 10-K · filed 2010-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |